The biotech tantalized investors with a very promising data update.
It will take a lot, but this goal isn't out of reach for these stocks.
A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy.
This week, the Dow Jones Industrial Average added Amazon to its lineup in a monumental shift for the oldest U.S. stock market index. But based on those same arguments, should the Dow also include AI chip...
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.
Has Amgen been a market-beating stock?
In a new disclosure filed today, U.S. Senator Tommy Tuberville reported the sale of $15,001 - $50,000 of Amgen Inc. - Common Stock, in a trade that took place on January 19. Since that trade was made,...
Both of these pharma stocks have entered the lucrative weight-loss drug market, but one has stronger fundamentals and better long-term prospects.
Investors interested in a steadily rising stream of passive income will find what they're looking for with these dividend payers.